Physician profile
Mark Alan Moran
NPI 1881738219
$6,113.80
in general payments reported to CMS, 2019-2025
24 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $889 · 2021: $968 · 2022: $812 · 2023: $833 · 2024: $407 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,970.89 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $1,270.67 | 2021-2025 | Synchromedii, Accurian, Intellis Adaptivestim |
| Boston Scientific Corporation | $976.90 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Infinion 16 |
| Si-Bone, INC. | $413.82 | 2019-2023 | |
| Medtronic USA, INC. | $294.19 | 2019-2020 | |
| Allergan, INC. | $235.29 | 2019-2022 | |
| Spr Therapeutics, INC | $181.09 | 2025 | Sprint Pns System |
| Nevro Corp. | $179.15 | 2023-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.55 | 2022-2024 | Relistor |
| Abbvie INC. | $55.93 | 2022-2023 | |
| Relievant Medsystems, INC. | $54.51 | 2023 | Intracept |
| Fidia Pharma USA INC. | $50.20 | 2023-2025 | Triluron, Hymovis, Hyalgan |
| Teva Pharmaceuticals USA, INC. | $46.38 | 2019 | |
| Almatica Pharma LLC | $45.09 | 2022 | |
| Globus Medical, INC. | $39.35 | 2025 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $33.71 | 2025 | |
| Mdd US Operations, LLC | $31.96 | 2019 | |
| Scilex Pharmaceuticals INC. | $28.34 | 2019 | |
| Averitas Pharma INC. | $25.71 | 2023 | Qutenza |
| Nalu Medical, INC. | $21.64 | 2024 | Nalu Neurostimulation System |
| Painteq LLC | $19.96 | 2024 | Painteq |
| Azurity Pharmaceuticals, INC. | $16.43 | 2025 | Horizant |
| Tonix Medicines, INC. | $15.55 | 2025 | Tonmya |
| Biodelivery Sciences International, INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.